These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 21641696)

  • 1. Combined SVM-based and docking-based virtual screening for retrieving novel inhibitors of c-Met.
    Xie QQ; Zhong L; Pan YL; Wang XY; Zhou JP; Di-Wu L; Huang Q; Wang YL; Yang LL; Xie HZ; Yang SY
    Eur J Med Chem; 2011 Sep; 46(9):3675-80. PubMed ID: 21641696
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of novel Pim-1 kinase inhibitors by a hierarchical multistage virtual screening approach based on SVM model, pharmacophore, and molecular docking.
    Ren JX; Li LL; Zheng RL; Xie HZ; Cao ZX; Feng S; Pan YL; Chen X; Wei YQ; Yang SY
    J Chem Inf Model; 2011 Jun; 51(6):1364-75. PubMed ID: 21618971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of novel mGluR1 antagonists: a multistep virtual screening approach based on an SVM model and a pharmacophore hypothesis significantly increases the hit rate and enrichment factor.
    Li GB; Yang LL; Feng S; Zhou JP; Huang Q; Xie HZ; Li LL; Yang SY
    Bioorg Med Chem Lett; 2011 Mar; 21(6):1736-40. PubMed ID: 21316965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of novel Bruton's tyrosine kinase inhibitors using a hybrid protocol of virtual screening approaches based on SVM model, pharmacophore and molecular docking.
    Wan HL; Wang ZR; Li LL; Cheng C; Ji P; Liu JJ; Zhang H; Zou J; Yang SY
    Chem Biol Drug Des; 2012 Sep; 80(3):366-73. PubMed ID: 22594639
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retrieving novel C5aR antagonists using a hybrid ligand-based virtual screening protocol based on SVM classification and pharmacophore models.
    Qing XY; Zhang CH; Li LL; Ji P; Ma S; Wan HL; Wang ZR; Zou J; Yang SY
    J Biomol Struct Dyn; 2013; 31(2):215-23. PubMed ID: 22831459
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of CK2 inhibitors with new scaffolds by a hybrid virtual screening approach based on Bayesian model; pharmacophore hypothesis and molecular docking.
    Di-wu L; Li LL; Wang WJ; Xie HZ; Yang J; Zhang CH; Huang Q; Zhong L; Feng S; Yang SY
    J Mol Graph Model; 2012 Jun; 36():42-7. PubMed ID: 22516037
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of novel fatty acid synthase (FAS) inhibitors based on the structure of ketoaceyl synthase (KS) domain.
    Zeng XF; Li WW; Fan HJ; Wang XY; Ji P; Wang ZR; Ma S; Li LL; Ma XF; Yang SY
    Bioorg Med Chem Lett; 2011 Aug; 21(16):4742-4. PubMed ID: 21752639
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A new Met inhibitory-scaffold identified by a focused forward chemical biological screen.
    Patané S; Pietrancosta N; Hassani H; Leroux V; Maigret B; Kraus JL; Dono R; Maina F
    Biochem Biophys Res Commun; 2008 Oct; 375(2):184-9. PubMed ID: 18703015
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of a novel and potent series of thieno[3,2-b]pyridine-based inhibitors of c-Met and VEGFR2 tyrosine kinases.
    Claridge S; Raeppel F; Granger MC; Bernstein N; Saavedra O; Zhan L; Llewellyn D; Wahhab A; Deziel R; Rahil J; Beaulieu N; Nguyen H; Dupont I; Barsalou A; Beaulieu C; Chute I; Gravel S; Robert MF; Lefebvre S; Dubay M; Pascal R; Gillespie J; Jin Z; Wang J; Besterman JM; MacLeod AR; Vaisburg A
    Bioorg Med Chem Lett; 2008 May; 18(9):2793-8. PubMed ID: 18434145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Virtual screening of selective multitarget kinase inhibitors by combinatorial support vector machines.
    Ma XH; Wang R; Tan CY; Jiang YY; Lu T; Rao HB; Li XY; Go ML; Low BC; Chen YZ
    Mol Pharm; 2010 Oct; 7(5):1545-60. PubMed ID: 20712327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis and structure-activity relationships of novel biarylamine-based Met kinase inhibitors.
    Williams DK; Chen XT; Tarby C; Kaltenbach R; Cai ZW; Tokarski JS; An Y; Sack JS; Wautlet B; Gullo-Brown J; Henley BJ; Jeyaseelan R; Kellar K; Manne V; Trainor GL; Lombardo LJ; Fargnoli J; Borzilleri RM
    Bioorg Med Chem Lett; 2010 May; 20(9):2998-3002. PubMed ID: 20382527
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovering potent inhibitors against c-Met kinase: molecular design, organic synthesis and bioassay.
    Liang Z; Ding X; Ai J; Kong X; Chen L; Chen L; Luo C; Geng M; Liu H; Chen K; Jiang H
    Org Biomol Chem; 2012 Jan; 10(2):421-30. PubMed ID: 22108637
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The discovery of benzanilides as c-Met receptor tyrosine kinase inhibitors by a directed screening approach.
    Allen JV; Bardelle C; Blades K; Buttar D; Chapman L; Colclough N; Dossetter AG; Garner AP; Girdwood A; Lambert C; Leach AG; Law B; Major J; Plant H; Slater AM
    Bioorg Med Chem Lett; 2011 Sep; 21(18):5224-9. PubMed ID: 21835616
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor.
    Pan BS; Chan GK; Chenard M; Chi A; Davis LJ; Deshmukh SV; Gibbs JB; Gil S; Hang G; Hatch H; Jewell JP; Kariv I; Katz JD; Kunii K; Lu W; Lutterbach BA; Paweletz CP; Qu X; Reilly JF; Szewczak AA; Zeng Q; Kohl NE; Dinsmore CJ
    Cancer Res; 2010 Feb; 70(4):1524-33. PubMed ID: 20145145
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Virtual screening of Abl inhibitors from large compound libraries by support vector machines.
    Liu XH; Ma XH; Tan CY; Jiang YY; Go ML; Low BC; Chen YZ
    J Chem Inf Model; 2009 Sep; 49(9):2101-10. PubMed ID: 19689138
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification and synthesis of N'-(2-oxoindolin-3-ylidene)hydrazide derivatives against c-Met kinase.
    Liang Z; Zhang D; Ai J; Chen L; Wang H; Kong X; Zheng M; Liu H; Luo C; Geng M; Jiang H; Chen K
    Bioorg Med Chem Lett; 2011 Jun; 21(12):3749-54. PubMed ID: 21561768
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacophore modelling and virtual screening for identification of new Aurora-A kinase inhibitors.
    Deng XQ; Wang HY; Zhao YL; Xiang ML; Jiang PD; Cao ZX; Zheng YZ; Luo SD; Yu LT; Wei YQ; Yang SY
    Chem Biol Drug Des; 2008 Jun; 71(6):533-9. PubMed ID: 18410307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Importance of molecular computer modeling in anticancer drug development.
    Geromichalos GD
    J BUON; 2007 Sep; 12 Suppl 1():S101-18. PubMed ID: 17935268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug development of MET inhibitors: targeting oncogene addiction and expedience.
    Comoglio PM; Giordano S; Trusolino L
    Nat Rev Drug Discov; 2008 Jun; 7(6):504-16. PubMed ID: 18511928
    [TBL] [Abstract][Full Text] [Related]  

  • 20. N3-arylmalonamides: a new series of thieno[3,2-b]pyridine based inhibitors of c-Met and VEGFR2 tyrosine kinases.
    Saavedra O; Claridge S; Zhan L; Raeppel F; Granger MC; Raeppel S; Mannion M; Gaudette F; Zhou N; Isakovic L; Bernstein N; Déziel R; Nguyen H; Beaulieu N; Beaulieu C; Dupont I; Wang J; Macleod AR; Besterman JM; Vaisburg A
    Bioorg Med Chem Lett; 2009 Dec; 19(24):6836-9. PubMed ID: 19896842
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.